Advisory Committee on Immunization Practices
Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. Recommendations of the immunization practices advisory committee (ACIP)
Abstract
These recommendations include information on use of two vaccines recently licensed for use with infants: Haemophilus b Conjugate Vaccine (Diphtheria CRM197 Protein Conjugate) (HbOC), manufactured by Praxis Biologics, Inc., and Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PRP-OMP), manufactured by Merck Sharp and Dohme, newly licensed for use with infants. This statement also updates recommendations for use of these and other Haemophilus b conjugate vaccines with older children and adults.
Source and rights
Published by MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 1991. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- Advisory Committee on Immunization Practices
- Published
- 1991
- Applies to
- 🇺🇸 United States
- Scope
- National
- Journal
- MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports
- PubMed
- 1899280
- Added to Prognia
- 16 July 2026